arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

SCYNEXIS, Inc.

SCYX Health Care Biotechnology: Pharmaceutical Preparations
$3.96
Today
as of Jul 22, 16:54 ET
Last 30 days -6.50% Jun 12 → Jul 22
$3.71 $4.04 $4.36 $4.69 $5.02 Jun 12 Jun 22 Jun 29 Jul 08 Jul 15 Jul 22
Open
$4.82
High
$4.99
Low
$4.55
Volume
$65,399
Avg Vol
$54,949
Mkt Cap
$39M
P/E (TTM)
—
Beta
—
52w High
$10.48
52w Low
$4.52
Div Yield
—
Shares Out
$62M

Recent Press Releases & News last 60 days · 1 item

Jun 30 · 12:00 PR GlobeNewswire
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Overview

52-week range
$4.52
$10
0% of range
Avg surprise (last 3)
-84.9%
Avg reaction (last 2)
-3.5%
50% positive
Latest IV / EM
553%
EM ±126.4% · $5 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.42$0.30$1.02$1.74$2.46 Actual $2.46Actual $-0.04Actual $0.01Actual $-0.30Actual $-0.06Actual $-0.17Est $-0.23Actual $-0.14Est $-0.23Actual $-0.17Actual $-0.42Est $-0.10 JunSepMarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-21M$-17M$-12M$-8M$-3M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Mon May 11, 2026Mar/2026 $-0.42 $-0.10 -320.0% -147.1% -10.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.17 — — — — financials
Wed Aug 13, 2025Jun/2025 $-0.14 $-0.23 +39.1% — — earnings
Thu May 15, 2025Mar/2025 $-0.17 $-0.23 +26.1% — +3.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.06 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.30 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.01 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.04 — — — — financials
Fri Jun 30, 2023Jun 2023 $2.46 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Aug 12, 2026Jun/2026OTHER -$0.40-$1.12 +64.3%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-17M—$-8M$-10M$-9M—$-10M$-9M
Net income$-21M—$-9M$-7M$-5M—$-3M$-14M
EPS (diluted)$-0.42—$-0.17$-0.14$-0.11—$-0.06$-0.30

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$37M$21M$15M$11M$7M$16M$29M$26M
Inventory————————
Total current assets$63M$40M$49M$56M$52M$72M$80M$95M
Total assets$78M$59M$51M$61M$68M$91M$99M$108M
Long-term debt————————
Total liabilities$36M$10M$15M$16M$17M$36M$41M$47M
Total equity$41M$49M$36M$44M$51M$55M$59M$60M

Implied volatility — last 90 days

255%875%1494%2114%2734% Jun 08 — IV 638% · EM ±84.3%Jun 09 — IV 705% · EM ±88.3%Jun 10 — IV 806% · EM ±95.2%Jun 11 — IV 1013% · EM ±111.9%Jun 12 — IV 1075% · EM ±109.9%Jun 15 — IV 1572% · EM ±113.7%Jun 16 — IV 1966% · EM ±116.1%Jun 17 — IV 2734% · EM ±114.2%Jun 19 — IV 520% · EM ±114.8%Jun 22 — IV 572% · EM ±119.4%Jun 23 — IV 595% · EM ±121.7%Jun 24 — IV 626% · EM ±125.3%Jun 25 — IV 657% · EM ±128.6%Jun 26 — IV 672% · EM ±128.6%Jun 29 — IV 678% · EM ±120.2%Jun 30 — IV 621% · EM ±106.9%Jul 01 — IV 587% · EM ±98.1%Jul 02 — IV 565% · EM ±91.4%Jul 03 — IV 585% · EM ±91.4%Jul 06 — IV 817% · EM ±113.1%Jul 07 — IV 879% · EM ±116.1%Jul 08 — IV 912% · EM ±114.3%Jul 09 — IV 992% · EM ±117.2%Jul 10 — IV 434% · EM ±47.9%Jul 13 — IV 1456% · EM ±121.7%Jul 14 — IV 1416% · EM ±102.4%Jul 15 — IV 1718% · EM ±101.4%Jul 16 — IV 802% · EM ±33.5%Jul 20 — IV 255% · EM ±60.3%Jul 21 — IV 528% · EM ±122.8%Jul 22 — IV 553% · EM ±126.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,162.23-0.1%
JNJ
Johnson & Johnson
$601.7B $255.02-0.2%
ABBV
AbbVie Inc.
$447.7B $256.20+1.1%
MRK
Merck & Company, Inc.
$307.2B $127.47-0.0%
PM
Philip Morris International Inc
$300.4B $195.00+0.3%
NVS
Novartis AG
$293.4B $152.73-0.2%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in